Toll Free: 1-888-928-9744

Cataract - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cataract - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cataract - Pipeline Review, H1 2015', provides an overview of the Cataract's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cataract
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cataract
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cataract Overview 7 Therapeutics Development 8 Pipeline Products for Cataract - Overview 8 Pipeline Products for Cataract - Comparative Analysis 9 Cataract - Therapeutics under Development by Companies 10 Cataract - Therapeutics under Investigation by Universities/Institutes 11 Cataract - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Cataract - Products under Development by Companies 14 Cataract - Products under Investigation by Universities/Institutes 15 Cataract - Companies Involved in Therapeutics Development 16 CalAsia Pharmaceuticals, Inc. 16 EyeGate Pharmaceuticals, Inc. 17 InSite Vision Incorporated 18 Laboratorios Sophia S.A. de C.V. 19 Laila Pharmaceuticals Pvt. Ltd. 20 Omeros Corporation 21 R-Tech Ueno, Ltd. 22 Cataract - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Combination Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 32 (bromfenac sodium + dexamethasone acetate) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 (sulfasalazine + Hyaluronic Acid) - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dexamethasone acetate - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LP-01309 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PRO-155 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RTU-007 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Cataract - Recent Pipeline Updates 45 Cataract - Dormant Projects 47 Cataract - Discontinued Products 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Cataract, H1 2015 8 Number of Products under Development for Cataract - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Cataract - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 16 Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 17 Cataract - Pipeline by InSite Vision Incorporated, H1 2015 18 Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2015 19 Cataract - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015 20 Cataract - Pipeline by Omeros Corporation, H1 2015 21 Cataract - Pipeline by R-Tech Ueno, Ltd., H1 2015 22 Assessment by Monotherapy Products, H1 2015 23 Assessment by Combination Products, H1 2015 24 Number of Products by Stage and Target, H1 2015 26 Number of Products by Stage and Mechanism of Action, H1 2015 28 Number of Products by Stage and Route of Administration, H1 2015 30 Number of Products by Stage and Molecule Type, H1 2015 31 Cataract Therapeutics - Recent Pipeline Updates, H1 2015 45 Cataract - Dormant Projects, H1 2015 47 Cataract - Discontinued Products, H1 2015 48



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify